Peking University Medical Pharmaceutical: Paliperidone Chemical Active Pharmaceutical Ingredient Marketing Application Approved

MetaMuskRat · 2026-03-18T23:51:37+00:00

People's Finance News, March 17 — Beida Pharmaceuticals ((000788)) announced on March 17 that the company recently received the "Approval Notice for Chemical Raw Material Drug Listing Application" issued and signed by the National Medical Products Administration. The generic drug name is paliperidone, with packaging specifications: 1kg/bag, 5kg/bag, 10kg/bag. Paliperidone is the main active metabolite of risperidone, a second-generation antipsychotic drug with strong control effects, high affinity, good tolerability, and high efficacy. It is mainly used for the treatment of schizophrenia in adults and adolescents aged 12-17 years (body weight ≥29kg).

MetaMuskRat

2026-03-18 23:51:37

People’s Financial News, March 17 — Peking University Medicine (000788) announced on March 17 that the company recently received the “Approval Notice for the Listing of Chemical Raw Material Drugs” issued by the National Medical Products Administration. The generic name of the drug is Paliperidone, with packaging specifications of 1kg/bag, 5kg/bag, and 10kg/bag. Paliperidone is the main active metabolite of Risperidone, a second-generation antipsychotic drug with strong control effects, high affinity, tolerability, and efficacy. It is mainly used for the treatment of schizophrenia in adults and adolescents aged 12-17 (weighing ≥29kg).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.